Highlights
• GlaxoSmithKline (GSK) Australia extends its services agreement with MedAdvisor for a further 12 months
• GSK will continue utilising MedAdvisor’s medication management platform to to provide relevant information for patients prescribed three medicines within GSK Australia’s respiratory portfolio.
• Agreement will generate Patient Engagement Program (PEP), formerly known as Medication Training and Adherence Campaigns (MTAC), revenue for MedAdvisor.
• Allows GSK Australia to leverage the MedAdvisor platform to support patients on the safe and effective use of these medicines.
Ann: GlaxoSmithKline Extends Service Agreement with MedAdvisor-MDR.AX, page-2
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MDR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.015(6.38%) |
Mkt cap ! $137.8M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 26.0¢ | 23.0¢ | $327.5K | 1.327M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 52500 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.5¢ | 161863 | 2 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| MDR (ASX) Chart |